

# Pfizer Independent Medical Education Grant Request for Proposals

Competitive Grant Program – Pfizer Internal Review Process

## *Evidence-Based Education on the Potential Impact of a Generic JAK Inhibitor on the Management of Rheumatologic Diseases*



### Overview

Generic JAK inhibitors are now available in many countries, coinciding with shifts in treatment paradigms and the emergence of new evidence across multiple rheumatologic diseases. With the anticipated availability of a generic JAK inhibitor in the United States in 2026, there is a critical need for awareness of existing knowledge gaps in clinical management with JAK inhibitors in various rheumatologic diseases, and the potential impact a generic JAK inhibitor could have in the treatment landscape of rheumatologic diseases. This underscores the importance of implementing data-driven, evidence-based educational interventions to ensure that evolving treatment considerations and emerging evidence are fully understood and appropriately applied in clinical practice.

This request for proposals is open to independent medical education proposals focused on improving healthcare professionals' understanding of the clinical impact, appropriate use, and evolving role of a generic JAK inhibitor in rheumatologic care.



### Geographic Scope

United States



### Project Types and Area of Interest

This RFP emphasizes the need for educational content that translates data-driven insights into practical clinical decision-making in rheumatologic care.

Proposed initiatives should conduct a thorough analysis of the available data and disseminate the resulting insights through evidence-based educational interventions that address the clinical implications and real-world impact of generic JAK inhibitor use in rheumatologic diseases.

Please see page 2 for full area of interest for this RFP.



### Key Milestones

**Submission Deadline**

**Anticipated Grant Award Notification**

**Anticipated Project Start Date**



21 May 2026



7 July 2026



October 2026



### Funding Range and Project Length

Individual projects requesting up to \$100,000 USD will be considered.

Maximum project length is 12 months.

## I. Eligibility

---

### Geographic Scope:

United States

### Applicant Eligibility Criteria:

The following may apply: medical doctor, nurse, healthcare institutions, professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.

Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).

If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.

The applicant must be the project/program lead or an authorized designee of such individual (e.g., project/program lead's grant coordinator).

The project/program lead must be an employee or contractor of the requesting organization.

Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.

For projects offering continuing education credit, the requesting organization must be accredited.

## II. Requirements

---

### Primary Area of Interest:

Rheumatology

### Specific Area of Interest for this RFP:

Educational projects eligible for Pfizer support should address the following components:

- Educational content: Programs should incorporate existing and any new data-driven insights and emerging real-world evidence to enable healthcare professionals to appropriately contextualize and apply information regarding the current use of JAK inhibitors for rheumatologic diseases within clinical practice, and the potential treatment paradigm shift with the entry of a generic JAK inhibitor. The education may feature case-based demonstrations that walk learners through patient workup, diagnostic considerations, therapeutic selection, monitoring strategies, and longitudinal follow-up in order to reinforce application of current evidence to individualized patient care. A defined period for data generation or retrieval and analysis is essential and should serve as the foundation of the educational activity, ensuring that all presented insights are grounded in systematically collected and rigorously evaluated evidence.
- Format: Priority will be given to face-to-face roundtable discussions that facilitate active engagement between faculty and participants. Additional educational formats — such as seminars, symposia, and live webinars — may also be considered.
- Educational outcomes: Applicants are encouraged to define clear educational metrics, such as estimated learner reach, demonstrated increases in knowledge through pre- and post-activity assessments, and the projected number of patients potentially affected by improved clinical practices. Publication of data driven commentary or perspective article authored by the educational leads is strongly encouraged to disseminate insights and further advance discourse in the field.

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered. In addition, proposals without the educational goals will not be considered.

### Target Audience:

Healthcare professionals involved in the diagnosis and long-term management of rheumatologic diseases, such as rheumatologists, primary care physicians, nurse practitioners, physician assistants, infusion/clinic nurses, pharmacists, specialty pharmacy clinicians, rheumatology fellows and trainees.

### Expected Approximate Monetary Range of Grant Applications:

Individual projects requesting up to \$100,000 USD will be considered. The estimated total available budget related to this RFP is \$100,000 USD.

Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

### Key Dates:



**IMPORTANT: Be advised applications submitted after the due date will not be reviewed.**

\*Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5)

### How to Submit:

**IMPORTANT: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.**

- Please go to [www.cybergrants.com/pfizer/knowledge](http://www.cybergrants.com/pfizer/knowledge) and sign in.

Note: there are individual portals for each grant application type. Please be sure to use the URL above.

First-time users should click “Create your password”.

- Click the “Start A New Knowledge Gap Application” button.

Requirements for submission:

- Complete all required sections of the online application
- **IMPORTANT:** Upload proposal (see Appendix) in the General RFP Submission field.

In the application:

- For the question “**Competitive Grant?**” select “**Yes**”
- Select the following Primary Area of Interest: **Rheumatology - General/Non-specific/Other – KG**
- Select the following Competitive Grant Program Name: **2026 I&I US JAKi Rheum IME**

## Questions:

- If you encounter any technical difficulties with the website, please click [here](#) or the “Technical Questions” link at the bottom of the page in CyberGrants.
- Please click [here](#) to view “Frequently Asked Questions” regarding the Competitive Grant Program.
- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Talita Honorato-Rzeszewicz ([talita.honorato-rzeszewicz@pfizer.com](mailto:talita.honorato-rzeszewicz@pfizer.com)), with the subject line “2026 I&I US JAKi Rheum IME”.

## Review and Approval Process:

Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

## Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

## Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.
- This RFP is supported by Pfizer Inc. and, if approved the payment will be issued by a Pfizer US based legal entity.

## About Pfizer Grants:

Pfizer supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

## Appendix

---

### **IMPORTANT: RFP Submission Requirements**

Applications will be accepted via the online portal listed in the [How to Submit](#) section. Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. When uploading your Project Proposal please ensure it addresses the following sections:

#### **Goals and Objectives**

Briefly state the overall goal of the project.

List the objectives you plan to meet with your project, in terms of learning and expected outcomes.

#### **Assessment of Need for the Project**

Include a description of your organization's needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.

#### **Target Audience**

Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

#### **Project Design and Methods**

Describe the planned project, the educational approach, and the way the planned methods address the established need.

#### **Innovation**

Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.

#### **Evaluation and Outcomes**

In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data.

Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.

#### **Dissemination Plan**

Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.

#### **Anticipated Project Timeline**

Provide an anticipated timeline for your project including project start/end dates.

#### **Additional Information**

If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.

#### **Organization Detail**

Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.

## Budget Detail

Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application.

While estimating your budget please keep the following items in mind:

Independent Medical Education Grants awarded by GMGP cannot be used to purchase therapeutic assets (prescription or non-prescription).

Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer. Please [click here](#) for details. General organizational running costs such as legal fees, insurance, heating and lighting etc. should be included in an Institutional Overhead (if required). These costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.

## Required Documents

Project Plan/Proposal or Meeting Agenda